Company Overview of Enumeral Biomedical Holdings, Inc.
Enumeral Biomedical Holdings, Inc. engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing antibodies against a number of classes of immunomodulatory proteins expressed on the surface of cells of the immune system for the treatment of cancer, autoimmune, and inflammatory diseases. Enumeral Biomedical Holdings, Inc. has a collaboration agreement with Merck Sharp & Dohme Corp.; and research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.
200 CambridgePark Drive
Cambridge, MA 02140
Founded in 2009
Key Executives for Enumeral Biomedical Holdings, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $174.6K
Co-Founder and Executive Chairman
Total Annual Compensation: $167.4K
Chief Accounting Officer, Vice President of Finance and Treasurer
Total Annual Compensation: $85.4K
Vice President of Business Development
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2014.
Enumeral Biomedical Holdings, Inc. Key Developments
Enumeral Biomedical Holdings, Inc.’s Novel Class of Potentially Allosteric Anti-PD-1 Antibodies Provides Additional Enhancement of T Cell Function
Nov 18 15
Enumeral Biomedical Holdings, Inc. announced that its novel class of potentially allosteric anti-PD-1 antibodies, when used in combination with conventional anti-PD-1 antagonists, provides additional enhancement of T cell function. It is believed that currently marketed anti-PD-1 antibodies must disrupt PD-1 interaction with PD-L1, a tumor cell-expressed negative regulatory ligand that suppresses T cell activity following PD-1 engagement. Enumeral’s antibodies block PD-L1-mediated immunosuppression, but do not disrupt PD-1 interaction with PD-L1. Enumeral’s researchers employed ex vivo methods to determine responsiveness of tumor infiltrating lymphocytes (TILs) derived from lung biopsies to various anti-PD-1 antibodies, measuring restoration of interferon gamma production, which is a key cytokine reflective of T cell activation. The Company’s researchers found that approximately 50% of assayed biopsies harbored TILs responsive to a series of anti-PD-1 antibodies. When a conventional anti-PD-1 antibody was combined with Enumeral’s antibody, interferon gamma levels were further increased above controls in a subset of the responsive samples. Additionally, Enumeral researchers have found that TILs isolated from lung tumor biopsies that display elevated TIM-3 expression levels have lower responsiveness to the effects of anti-PD-1 antibodies in ex vivo assays.
Enumeral Biomedical Holdings, Inc. Reports Unaudited Earnings Results for the Third Quarter Ended September 30, 2015
Nov 10 15
Enumeral Biomedical Holdings, Inc. reported unaudited earnings results for the third quarter ended September 30, 2015. For the quarter, the company reported total revenues of $483,825 against $70,408 a year ago. Loss from operations was $2,668,480 against $2,151,521 a year ago. Net income before income taxes was $618,284 against net loss before income taxes of $8,823,492 a year ago. Net income was $618,284 against net loss of $8,823,492 a year ago. This increase was primarily due to an increase in the change in fair value of derivative liabilities of $8,118,713 and an increase in revenues of $413,417, offset by an increase of $930,376 in research and development and general and administrative expenses. Net income diluted per share was $0.01 against net loss per diluted share of $0.22 a year ago. This increase in revenue is attributable to the company’s collaboration agreement with Merck and its grant from the National Cancer Institute.
Enumeral Biomedical Holdings, Inc. Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action
Sep 24 15
Enumeral Biomedical Holdings, Inc. announced the progress in its anti-PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company’s R&D pipeline, including its TIM-3 and LAG-3 antibody programs. Earlier this year, Enumeral announced the identification of antibodies that appear to bind to the PD-1 inhibitory checkpoint protein in a manner different from that of currently marketed anti-PD-1 antibodies, while retaining activity in cell-based assays. Enumeral reported that these novel antibodies do not appear to compete with currently marketed antibodies for binding to PD-1, nor do they appear to compete with PD-L1, providing further evidence of a differentiated mechanism of action Enumeral has isolated and sequenced more than 300 anti-PD-1 antibodies from primary B cells. The Company has humanized two lead antibodies and tested them in cell-based assays. As reported at the recent immunotherapy meeting, Enumeral’s novel family of antibodies exhibits a higher level of T cell activation in mixed lymphocyte reaction (MLR) and other assays than associated with currently-marketed antibodies, including: Enumeral’s lead antibodies demonstrated increased interferon gamma production as shown by MLR assay, which is designed to assess T cell effector function using primary human immune cells. These antibodies also demonstrated dose-dependent increases in T cell CD25 expression. In Enumeral’s TIM-3 program, the Company has isolated 124 TIM-3 binding antibodies to date. Enumeral’s bioinformatics analysis indicates desirable diversity, with the antibodies falling into 42 distinct clades that bind to TIM-3. Enumeral plans to apply its unique approach to cellular immune response profiling to further understand the utility of these different antibodies for modulation of different tumor infiltrating lymphocytes.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|